TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Presentations at the Heart Failure Society of America meeting reported additional early findings for cardiac microcurrent therapy, including a core-lab reanalysis of exercise-test data and results from a small study of a less invasive implant. Researchers and a discussant cautioned that the reported benefits need confirmation in larger, controlled studies; a 60-person sham-controlled trial is planned.
Researchers presented new early findings on cardiac microcurrent therapy (C-MIC) for heart failure at the Heart Failure Society of America’s annual meeting on October 13, while emphasizing that the results remain preliminary. A reanalysis of exercise-test data from a small trial and a 10-patient first-in-human study of a less invasive implant approach offer signals of possible benefit, but do not establish that the treatment works; a planned 60-person sham-controlled trial is expected to provide a more rigorous test.
In a post hoc analysis of the randomized C-MIC II trial, researchers reassessed six-month cardiopulmonary exercise test results using a blinded core laboratory. Among 42 participants in the reanalysis, the reported between-group changes favored C-MIC for several measures. Peak metabolic equivalents increased by 1.0 versus 0.1 in controls, and percent-predicted peak oxygen consumption increased by 13.8% versus 0.5%; both comparisons had a reported P value of 0.021. The absolute peak VO2 comparison was 208.7 versus 7.3 mL/min, with P=0.079, which did not meet the conventional threshold for statistical significance.
Dragana Kosevic, a physician at Cardiovascular Institute Dedinje in Belgrade, also reported a 2.70 mL/min/kg increase in weight-adjusted peak VO2 for the C-MIC group. She said the core-lab exercise-test findings supported functional benefits observed in the trial, while calling for larger randomized studies. The analysis is not a new randomized trial: it revisited existing data, and only five of seven C-MIC II sites contributed to the reanalysis.
A separate presentation described a subcutaneous version of the implant, with its generator and lead placed under the skin rather than through the surgical epicardial approach used in C-MIC II. Stefan Simovic of the University of Kragujevac reported matched comparisons involving 10 first-in-human C-MIC III patients, 10 surgical-implant patients from C-MIC II, and 10 matched controls from C-MIC II. The subcutaneous group had comparable changes in ejection fraction, six-minute walking distance and quality-of-life scores, but the small, nonrandomized comparison cannot establish equivalence or effectiveness.
A Less Invasive Route to Testing
If the subcutaneous approach proves effective and safe, it could make implantation less demanding than the earlier surgical method and allow researchers to test the therapy in a broader group of people with heart failure. The upcoming study is set to include people with ischemic as well as non-ischemic heart failure, expanding beyond the populations in the earlier trials.
For patients with reduced ejection fraction whose condition remains difficult to manage, a new device-based option could matter. But the numbers presented so far are too limited to show whether C-MIC improves outcomes that patients care about, such as symptoms, daily function, hospitalizations or survival. The striking exercise-test change drew skepticism at the meeting, underlining why a larger controlled study is needed before drawing conclusions.
cardiac microcurrent therapy device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Epicardial Implant to C-MIC IV
C-MIC was developed around the theory that altering electrical fields in heart muscle could affect myocardial stiffness and ventricular function. The source report describes a proposed mechanism in which microcurrents may shift activated fibroblasts toward a less fibrogenic state. That is a proposed explanation, not proof of how the therapy works in patients.
The earlier C-MIC II trial randomized 65 people with refractory, non-ischemic heart failure with reduced ejection fraction. The surgical implant was associated with improvements in measures including ejection fraction, symptoms, functional capacity and quality of life compared with controls. Peak VO2, however, only trended toward benefit in the original report and was not statistically significant. The later reanalysis used a blinded core lab because the original exercise-test values were reported by sites, leaving potential differences in how tests were performed or interpreted.
Initial six-month C-MIC III results, reported earlier in 2026, showed improvements from baseline in ejection fraction, walking distance and KCCQ quality-of-life scores, according to the source report. C-MIC III was a first-in-human study with only 10 subcutaneous recipients. Those findings are preliminary and are not a substitute for a randomized comparison.
“I am highly skeptical of the magnitude of the benefit that you folks are showing, but I remain actually very enthusiastic about moving this forward.”
— John Teerlink, San Francisco VA Health Care System and UCSF Medical Center
heart failure microcurrent implant
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Small Studies Leave Open Questions
The current evidence does not show whether C-MIC produces durable clinical benefits or how its effects compare with established care. C-MIC II enrolled only several dozen people and used an open-label design; its core-lab reanalysis involved 42 participants and excluded data from two of the seven trial sites. C-MIC III’s subcutaneous findings came from just 10 implanted patients and a matched comparison rather than random assignment.
Safety and device compatibility also need study. Teerlink raised questions about possible interactions with existing devices and treatments, including implantable cardioverter-defibrillators, cardiac resynchronization therapy, baroreflex activation therapy, cardiac contractility modulation and coronary stents. The meeting report did not provide answers to those questions or detailed safety results for the new approach. It is also unclear from the presented material when the next trial will begin or when results will be available.
As an affiliate, we earn on qualifying purchases.
C-MIC IV Will Test the Signal
The next major test described at the meeting is C-MIC IV, a planned sham-controlled crossover trial involving 60 people with left ventricular ejection fractions of 20% to 40%. According to Simovic, participants will receive the subcutaneous device, and the study will include both ischemic and non-ischemic heart failure.
The trial’s sham control is intended to provide a stronger basis for separating treatment effects from expectations and other influences than the earlier open-label evidence. Until its design, enrollment, safety findings and outcomes are reported, the results presented at HFSA should be treated as early research signals rather than proof that C-MIC is an effective heart failure treatment.
heart failure exercise test monitor
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is cardiac microcurrent therapy?
C-MIC is an implanted system designed to deliver microcurrents to the heart. Researchers propose that the electrical stimulation could affect heart muscle structure and function, but the mechanism and clinical benefits remain under study.
Did the C-MIC II reanalysis prove that the therapy works?
No. It was a post hoc reanalysis of existing trial data, not a new trial. Some exercise-test measures favored C-MIC, while the absolute peak VO2 comparison had a reported P value of 0.079. Larger randomized studies are needed to confirm the findings.
How does the subcutaneous implant differ?
The subcutaneous approach places the generator and lead under the skin, with lead position checked using fluoroscopy. The earlier C-MIC II approach used a surgical epicardial implant. The new approach has been studied in a very small first-in-human group.
What is the planned C-MIC IV trial?
Researchers described a planned 60-person sham-controlled crossover study of the subcutaneous device. It is intended to include participants with ischemic and non-ischemic heart failure and ejection fractions of 20% to 40%.
Are safety and interactions with other heart devices known?
The meeting report leaves these questions unresolved. A discussant raised possible interactions with implanted cardiac devices and coronary stents; further study is needed to establish safety and compatibility.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
